C$1,545,500 over 2 Years
- Yi-Wen Chen (Children’s National Hospital, Washington, DC)
- Giorgio Tasca & Enzo Ricci (Università Cattolica del Sacro Cuore – Rome)
- Sabrina Sacconi (Centre Hospitalier Universitaire de Nice)
Biomarkers are used to predict results in clinical trials. They are a critical part of the toolkit. Ideally, biomarkers should provide an immediate measure of how well a drug is performing. Drug companies want to succeed – or fail – fast. Unfortunately, there are no such “fast” biomarkers available for FSHD. This is a major disincentive for drug companies to undertake expensive clinical trials in FSHD.
These grants sponsor three research projects all focussed on “blood biomarkers” which could dramatically speed up FSHD clinical trials – and reduce costs.
The FSHD Canada Foundation acknowledges the generous support of Solve FSHD towards the funding of this grant.